Healthcare Industry News: bone graft
News Release - September 25, 2013
RTI Surgical(TM) Announces First Implantation of map3(TM) Cellular Allogeneic Bone Graft in a Foot and Ankle ProcedureALACHUA, Fla.--(Healthcare Sales & Marketing Network)--RTI Surgical Inc. (RTI) (RTIX), a global surgical implant company, is pleased to announce the first implantation of the company’s map3™ Cellular Allogeneic bone graft implant in a foot and ankle procedure.
Dr. Michael Lyons, DPM, an associate member of the American College of Foot and Ankle Surgeons, performed the implantation during a medial column fusion procedure in Indiana. He used the implant’s chips allograft configuration, one of two configurations that will be available.
“Taking into account the published MAPC™ research, I decided to use map3 in a complex case with an immune-compromised patient because it would support the patient’s ability to heal,” said Dr. Lyons. “I was impressed by the ease of use – it required very little time to prepare with simple instructions for preparation. I will definitely use map3 again when it’s appropriate for the patient’s case.”
Map3 cellular allogeneic bone graft is a natural and safe alternative to autograft. Map3 provides a streamlined approach to bone grafting and supplies the three elements necessary for bone repair—osteogenesis, osteoinduction and osteoconduction — in a single allograft. Map3 incorporates multipotent adult progenitor cell-based (MAPC-based) technology with stem cells isolated from the same donor as the other bone material. The MAPC technology, licensed from Athersys, Inc. for this orthopedic application, represents a distinctive type of stem cell with recognized angiogenic and immuno-modulatory properties. Map3 will be available in multiple configurations and sizes, providing bone grafting options for various bone repair, reconstruction and fusion procedures.
“Dr. Lyons’ successful use of map3 in a foot and ankle procedure is an exciting new development following its use in spine procedures,” said Brian K. Hutchison, RTI president and CEO. “The MAPC-based technology offers the greatest potential to create high quality, innovative implants for our surgeons and their patients and will greatly enhance our company’s orthobiologics offerings. We anticipate a limited market release of the implant later this year.”
About RTI Surgical Inc.
RTI Surgical is a leading global surgical implant company providing surgeons with safe biologic, metal and synthetic implants. Committed to advancing science, safety and innovation, RTI’s implants are used in sports medicine, general surgery, spine, orthopedic, trauma and cardiothoracic procedures and are distributed in nearly 50 countries. RTI is headquartered in Alachua, Fla., and has four manufacturing facilities throughout the U.S. and Europe. RTI is accredited in the U.S. by the American Association of Tissue Banks and is a member of AdvaMed. For more information, please visit www.rtix.com.
This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management’s current expectations, estimates and projections about our industry, our management's beliefs and certain assumptions made by our management. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," variations of such words and similar expressions are intended to identify such forward-looking statements. In addition, except for historical information, any statements made in this communication about anticipated financial results, growth rates, new product introductions, future operational improvements and results or regulatory actions or approvals or changes to agreements with distributors also are forward-looking statements. These statements are not guarantees of future performance and are subject to risks and uncertainties, including the risks described in public filings with the U.S. Securities and Exchange Commission (SEC). Our actual results may differ materially from the anticipated results reflected in these forward-looking statements. Copies of the company's SEC filings may be obtained by contacting the company or the SEC or by visiting RTI's website at www.rtix.com or the SEC's website at www.sec.gov.
Source: RTI Surgical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.